A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease

The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. In this art...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosli, Mahmoud H., Al-Harbi, Othman, Feagan, Brian G., Almadi, Majid A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Special Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542416/
https://www.ncbi.nlm.nih.gov/pubmed/26228361
http://dx.doi.org/10.4103/1319-3767.161635
_version_ 1782386527593037824
author Mosli, Mahmoud H.
Al-Harbi, Othman
Feagan, Brian G.
Almadi, Majid A.
author_facet Mosli, Mahmoud H.
Al-Harbi, Othman
Feagan, Brian G.
Almadi, Majid A.
author_sort Mosli, Mahmoud H.
collection PubMed
description The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF-α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents.
format Online
Article
Text
id pubmed-4542416
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-45424162015-08-28 A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease Mosli, Mahmoud H. Al-Harbi, Othman Feagan, Brian G. Almadi, Majid A. Saudi J Gastroenterol Special Communication The objective of this position statement from the Saudi Gastroenterology Association is to guide gastroenterologists on the use of tumor necrosis factor-alfa (TNF-α) antagonists for the treatment of the idiopathic inflammatory bowel diseases, Crohn's disease, and ulcerative colitis. In this article, we summarize the relevant literature regarding the safety and efficacy of TNF-α antagonists, highlight relevant safety concerns specific to the environment in Saudi Arabia, and provide specific recommendations for the use of these agents. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4542416/ /pubmed/26228361 http://dx.doi.org/10.4103/1319-3767.161635 Text en Copyright: © Saudi Journal of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Special Communication
Mosli, Mahmoud H.
Al-Harbi, Othman
Feagan, Brian G.
Almadi, Majid A.
A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
title A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
title_full A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
title_fullStr A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
title_full_unstemmed A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
title_short A Saudi Gastroenterology Association Position Statement on the Use of Tumor Necrosis Factor-alfa Antagonists for the Treatment of Inflammatory Bowel Disease
title_sort saudi gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease
topic Special Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542416/
https://www.ncbi.nlm.nih.gov/pubmed/26228361
http://dx.doi.org/10.4103/1319-3767.161635
work_keys_str_mv AT moslimahmoudh asaudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease
AT alharbiothman asaudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease
AT feaganbriang asaudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease
AT almadimajida asaudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease
AT moslimahmoudh saudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease
AT alharbiothman saudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease
AT feaganbriang saudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease
AT almadimajida saudigastroenterologyassociationpositionstatementontheuseoftumornecrosisfactoralfaantagonistsforthetreatmentofinflammatoryboweldisease

Ejemplares similares